medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2022, Number 2

<< Back Next >>

Alerg Asma Inmunol Pediatr 2022; 31 (2)

Intralymphatic immunotherapy

Arce-Estrada GE, Arce-Estrada J, Contreras-Verduzco FA, Espinosa-Padilla SE

Language: Spanish
References: 56
Page: 43-50
PDF size: 175.65 Kb.


ABSTRACT

Intralymphatic immunotherapy consists of injecting minimal quantities of allergen extracts into the lymph nodes and is a more efficient route of administration than the others, since the lymph nodes are secondary lymphoid organs and contain a greater number of antigen-presenting cells. This allows to reduce the number of injections and the dose of the allergen and also contain low numbers of mast cells and basophils, which theoretically makes allergic hypersensitivity reactions less likely to occur. However, intralymphatic immunotherapy currently has few studies.


REFERENCES

  1. Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005; 116 (2): 377-383. doi: 10.1016/j.jaci.2005.05.017.

  2. Asher MI, Montefort S, Bjorkstén B, Lai CK, Strachan DP, Weiland SK, Williams H; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006; 368 (9537): 733-743. doi: 10.1016/S0140-6736(06)69283-0. Erratum in: Lancet. 2007; 370 (9593): 1128.

  3. Bjorkstén B, Clayton T, Ellwood P, Stewart A, Strachan D; ISAAC Phase III Study Group. Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008; 19 (2): 110-124. doi: 10.1111/j.1399-3038.2007.00601.x.

  4. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86: 8-160. doi: 10.1111/j.1398-9995.2007.01620.x.

  5. Senti G, Kündig TM. Intralymphatic immunotherapy. World Allergy Organ J. 2015; 8 (1): 9. doi: 10.1186/s40413-014-0047-7.

  6. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008; 105 (46): 17908-17912. doi: 10.1073/pnas.0803725105.

  7. Jacobsen L, Wahn U, Bilo MB. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy. 2012; 2: 8. doi: 10.1186/2045-7022-2-8.

  8. Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol. 2010; 125 (2 Suppl 2): S306-313. doi: 10.1016/j.jaci.2009.10.064.

  9. Alvaro-Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, Arasi S et al. EAACI Allergen Immunotherapy User's guide. Pediatr Allergy Immunol. 2020; 31 Suppl 25 (Suppl 25):1-101. doi: 10.1111/pai.13189.

  10. Cappella A, Durham SR. Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother. 2012; 8 (10): 1499-1512. doi: 10.4161/hv.21629.

  11. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998; 102 (4 Pt 1):558-562. doi: 10.1016/s0091-6749(98)70271-4.

  12. Calderon MA, Demoly P, Gerth van Wijk R, Bousquet J, Sheikh A, Frew A et al. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy. 2012; 2 (1): 20. doi: 10.1186/2045-7022-2-20.

  13. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015; 136 (3): 556-568. doi: 10.1016/j.jaci.2015.04.047.

  14. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007; 62 (8): 943-948. doi: 10.1111/j.1398-9995.2007.01451.x.

  15. Schmitt J, Schwarz K, Stadler E, Wüstenberg EG. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: results from a large retrospective cohort study. J Allergy Clin Immunol. 2015; 136 (6): 1511-1516. doi: 10.1016/j.jaci.2015.07.038.

  16. Martínez OBL, Pedroza MÁ, Contreras VFA. Inmunoterapia intralinfática para el manejo de patologías alérgicas en el paciente pediátrico. Revisión sistemática de ensayos clínicos. Alergia Asma Inmunol Pediatr. 2021; 30 (1): 5-12. Disponible en: https://dx.doi.org/10.35366/100111

  17. Rangel-Garza L, Larenas-Linnemann D, Rodríguez-Pérez N, Ortega-Martell JA, Oyoqui-Flores JJ. La práctica clínica de la inmunoterapia con alérgenos en México según 277 alergólogos encuestados durante un curso trianual [The clinical practice of allergen immunotherapy in Mexico according to 277 allergists who were surveyed during a three-year AIT course]. Rev Alerg Mex. 2020; 67 (1): 1-8. Spanish. doi: 10.29262/ram.v67i1.644.

  18. Senti G, Freiburghaus AU, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L et al. Intralymphatic Immunotherapy: Update and Unmet Needs. Int Arch Allergy Immunol. 2019; 178 (2): 141-149. doi: 10.1159/000493647.

  19. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987; 79 (4): 660-677. doi: 10.1016/s0091-6749(87)80164-1.

  20. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol. 1990; 86 (5): 775-780. doi: 10.1016/s0091-6749(05)80182-4.

  21. Stewart GE 2nd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol. 1992; 90 (4 Pt 1): 567-578. doi: 10.1016/0091-6749(92)90129-p. PMID: 1401640.

  22. Hellkvist L. Intralymphatic immunotherapy in allergic rhinitis - evaluating safety, efficacy and mechanisms. [Thesis for doctoral degree]. [Stockholm, Sweden]: Karolinska Institutet; 2020.

  23. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011; 127 (1 Suppl): S1-55. doi: 10.1016/j.jaci.2010.09.034. Epub 2010 Dec 3. Erratum in: J Allergy Clin Immunol. 2011; 127 (3): 840.

  24. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007; 2007 (1): CD001936. doi: 10.1002/14651858.CD001936.pub2.

  25. Leatherman BD, Khalid A, Lee S, McMains K, Peltier J, Platt MP et al. Dosing of sublingual immunotherapy for allergic rhinitis: evidence-based review with recommendations. Int Forum Allergy Rhinol. 2015; 5 (9): 773-783. doi: 10.1002/alr.21561.

  26. Jutel M, Bartkowiak-Emeryk M, Breborowicz A, Cichocka-Jarosz E, Emeryk A, Gawlik R et al. Sublingual immunotherapy (SLIT)--indications, mechanism, and efficacy: position paper prepared by the Section of Immunotherapy, Polish Society of Allergy. Ann Agric Environ Med. 2016; 23 (1): 44-53. doi: 10.5604/12321966.1196851.

  27. Cox L, Calderon MA. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe. Curr Med Res Opin. 2010; 26 (12): 2723-2733. doi: 10.1185/03007995.2010.528647.

  28. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012; 129 (5): 1290-1296. doi: 10.1016/j.jaci.2012.02.026.

  29. Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009; 9 (6): 537-543. doi: 10.1097/ACI.0b013e3283310ff7.

  30. Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013; 131 (2): 412-420. doi: 10.1016/j.jaci.2012.10.056.

  31. Martínez-Gómez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kündig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009; 150 (1): 59-65. doi: 10.1159/000210381.

  32. Nilsson BO, Svalander PC, Larsson A. Immunization of mice and rabbits by intrasplenic deposition of nanogram quantities of protein attached to Sepharose beads or nitrocellulose paper strips. J Immunol Methods. 1987; 99 (1): 67-75. doi: 10.1016/0022-1759(87)90033-0.

  33. Von Moos S, Kündig TM, Senti G. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin North Am. 2011; 31 (2): 391-406, xi. doi: 10.1016/j.iac.2011.02.012.

  34. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kündig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev. 1997; 156: 199-209. doi: 10.1111/j.1600-065x.1997.tb00969.x.

  35. Johansen P, Senti G, Martinez Gomez JM, Storni T, von Beust BR, Wüthrich B et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy. 2005; 35 (12): 1591-1598. doi: 10.1111/j.1365-2222.2005.02384.x.

  36. Johansen P, Senti G, Martínez Gómez JM, Wüthrich B, Bot A, Kündig TM. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur J Immunol. 2005; 35 (12): 3591-3598. doi: 10.1002/eji.200535076.

  37. Wang K, Zheng R, Chen Y, Yu Q, Zhong H, Xiao P et al. Clinical efficacy and safety of cervical intralymphatic immunotherapy for house dust mite allergic rhinitis: a pilot study. Am J Otolaryngol. 2019; 40 (6): 102280. doi: 10.1016/j.amjoto.2019.102280.

  38. Hoang MP, Seresirikachorn K, Chitsuthipakorn W, Snidvongs K. Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Rhinology. 2021; 59 (3): 236-244. doi: 10.4193/Rhin20.572.

  39. Kedl RM, Kappler JW, Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol. 2003; 15 (1): 120-127. doi: 10.1016/s0952-7915(02)00009-2.

  40. Siegrist CA. Vaccine immunology. In: Plotkin SA, editor. Vaccines. 6th edition. Philadelphia: Saunders; 2013. 14-32.

  41. Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013; 131 (1): 103-9.e1-7. doi: 10.1016/j.jaci.2012.07.028.

  42. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013; 132 (5): 1248-1252.e5. doi: 10.1016/j.jaci.2013.07.033.

  43. Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014; 133 (3): 930-931. doi: 10.1016/j.jaci.2013.11.036.

  44. Senti G, Kündig TM. Novel delivery routes for allergy immunotherapy: intralymphatic, epicutaneous, and intradermal. Immunol Allergy Clin North Am. 2016; 36 (1): 25-37. doi: 10.1016/j.iac.2015.08.006.

  45. Lee SP, Choi SJ, Joe E, Lee SM, Lee MW, Shim JW et al. A pilot study of intralymphatic immunotherapy for house dust mite, cat, and dog allergies. Allergy Asthma Immunol Res. 2017; 9 (3): 272-277. doi: 10.4168/aair.2017.9.3.272.

  46. Park HJ, Kim SH, Shin YS, Park CH, Cho ES, Choi SJ et al. Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial. Respir Res. 2021; 22 (1): 170. doi: 10.1186/s12931-021-01766-0.

  47. Skaarup SH, Schmid JM, Skjold T, Graumann O, Hoffmann HJ. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial. J Allergy Clin Immunol. 2021; 147 (3): 1011-1019. doi: 10.1016/j.jaci.2020.07.002.

  48. Thompson CP, Silvers S, Shapiro MA. Intralymphatic immunotherapy for mountain cedar pollinosis: A randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2020; 125 (3): 311-318.e2. doi: 10.1016/j.anai.2020.04.030.

  49. Terada T, Omura S, Kikuoka Y, Suzuki M, Inaka Y, Inui T et al. Sustained effects of intralymphatic pollen-specific immunotherapy on Japanese cedar pollinosis. Rhinology. 2020; 58 (3): 241-247. doi: 10.4193/Rhin19.301.

  50. Konradsen JR, Grundström J, Hellkvist L, Tran TAT, Andersson N, Gafvelin G,et al. Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: A randomized trial. J Allergy Clin Immunol. 2020; 145 (3): 1005-1007.e7. doi: 10.1016/j.jaci.2019.11.017.

  51. Hellkvist L, Hjalmarsson E, Kumlien Georén S, Karlsson A, Lundkvist K, Winqvist O et al. Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2018; 142 (4): 1338-1341.e9. doi: 10.1016/j.jaci.2018.05.030.

  52. Ahlbeck L, Ahlberg E, Nystrom U, Bjorkander J, Jenmalm MC. Intralymphatic allergen immunotherapy against pollen allergy: A 3-year open follow-up study of 10 patients. Ann Allergy Asthma Immunol. 2018; 121 (5): 626-627. doi: 10.1016/j.anai.2018.07.010.

  53. Hylander T, Larsson O, Petersson-Westin U, Eriksson M, Kumlien Georén S, Winqvist O et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2016; 17: 10. doi: 10.1186/s12931-016-0324-9.

  54. Schmid JM, Nezam H, Madsen HH, Schmitz A, Hoffmann HJ. Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study. Clin Transl Allergy. 2016; 6: 19. doi: 10.1186/s13601-016-0107-x.

  55. Skaarup SH, Schmid JM, Skjold, T, Graumann O, Hoffmann HJ. ILIT is a similarly effective treatment of grass pollen induced rhinitis for patients with moderate/severe and mild symptoms. Allergy. 2016; 3: 94. Available in: https://doi.org/10.1111/all.12970

  56. Patterson AM, Bonny AE, Shiels WE 2nd, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016; 116 (2): 168-170. doi: 10.1016/j.anai.2015.11.010.




2020     |     www.medigraphic.com